These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4129950)

  • 1. Effect of polyene macrolid compounds on plasma cholesterol and luteinizing hormone in man.
    Lunglmayr G; Spona J
    Int Urol Nephrol; 1973 Apr; 5(2):223-7. PubMed ID: 4129950
    [No Abstract]   [Full Text] [Related]  

  • 2. A double blind trial of a polyene macrolide--nystatin--in the treatment of benign prostatic hyperplasia in man.
    Bourke JB; Griffin JP; Theodorides P
    Br J Urol; 1974 Aug; 46(4):463-6. PubMed ID: 4137500
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of treatment with mepartricin on the plasma androgen and gonadotropin concentrations in subjects with benign prostatic hypertrophy].
    Sciarra F; Bianchi P; Toscano V
    Minerva Urol Nefrol; 1988; 40(2 Suppl):10-2. PubMed ID: 2460936
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone.
    Casarosa C; Cosci di Coscio M; Fratta M
    Clin Ther; 1988; 10(5):585-8. PubMed ID: 2485240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a polyene macrolide: nystatin.
    Theodorides P; Bourke JB; Griffin JP
    Proc R Soc Med; 1972 Feb; 65(2):130-1. PubMed ID: 4117438
    [No Abstract]   [Full Text] [Related]  

  • 6. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
    Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
    Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of chlormadinone acetate-pellet implantation on the volume of prostate, peripheral blood levels of sex hormones and semen quality in the dog.
    Shimizu M; Tsutsui T; Kawakami E; Hori T; Fujita M; Orima H; Ogasa A
    J Vet Med Sci; 1995 Jun; 57(3):395-9. PubMed ID: 7548388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of benign prostatic hyperplasia with the preparation Gentos].
    Pecherskiĭ AV; Aleksandrov VP; Mazurov VI; Kniaz'kin IV; Zeziulin PN; Nikolaeva EV
    Urologiia; 2000; (5):16-7. PubMed ID: 11392216
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
    Katayama T; Umeda K; Kazama T
    Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of osaterone acetate administration on prostatic regression rate, peripheral blood hormone levels and semen quality in dogs with benign prostatic hypertrophy.
    Tsutsui T; Hori T; Shimizu M; Tatsuzawa C; Kawakami E
    J Vet Med Sci; 2001 Apr; 63(4):453-6. PubMed ID: 11346183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol.
    Matzkin H; Chen J; Lewyshon O; Ayalon D; Braf Z
    Horm Metab Res; 1992 Oct; 24(10):498-9. PubMed ID: 1281461
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
    Eri LM; Urdal P
    Eur Urol; 1995; 27(4):274-9. PubMed ID: 7544732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses of serum luteinizing hormone and follicle-stimulating hormone levels to synthetic luteinizing hormone-releasing hormone (LH-RH) in various forms of testicular disorders.
    Isurugi K; Wakabayashi K; Fukutani K; Takayasu H; Tamaoki BI
    J Clin Endocrinol Metab; 1973 Oct; 37(4):533-9. PubMed ID: 4582573
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1331-3. PubMed ID: 2437142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of antiestrogen, antiandrogen, and the prolactin inhibitor 2 bromo-alpha-ergocriptine on the stromal tissue of human benign prostatic hyperplasia. Correlation of stereological data and plasma hormones.
    Bartsch G; Oberholzer M; Rohr HP
    Invest Urol; 1981 Jan; 18(4):308-12. PubMed ID: 6161105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pituitary hormones in prostatic adenoma].
    Gerasimova TsI; Men'shikov VV; Buniatin AF; Smirnov AN; Bol'shakova TD
    Sov Med; 1985; (2):80-3. PubMed ID: 2581323
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum hormone levels in benign prostatic hyperplasia.
    Sköldefors H; Blomstedt B; Carlström K
    Scand J Urol Nephrol; 1978; 12(2):111-4. PubMed ID: 80820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostatectomy--induced decrease in an enhanced serum testosterone concentration in patients with prostatic hyperplasia and its pathophysiological implications.
    Baranowska B; Zgliczyński S
    Endokrynol Pol; 1979; 30(1):75-87. PubMed ID: 85550
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men.
    Ortega E; Ruiz E; Mendoza MC; Martin-Andres A; Osorio C
    Experientia; 1979 Jun; 35(6):844-5. PubMed ID: 89045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.